Effect of linkage of transduction domain sequences to a lymphoma idiotype DNA vaccine on vaccine effectiveness

Abdel Kader Ashour, Jason L. Petersen, Mary M. McIlhaney, Julie Marie Vose, Joyce C Solheim

Research output: Contribution to journalArticle

Abstract

Patient idiotype-specific vaccines for treatment of non-Hodgkin's lymphoma have shown promise in clinical trials, encouraging efforts to enhance the effectiveness of idiotype vaccines further. It has previously been found that for some other types of experimental vaccines, the addition of transduction domains has improved vaccine immunogenicity. Transduction domains are short amino acid sequences that are capable of increasing transport through cellular membranes. In this study, we tested murine B cell 38C13 lymphoma idiotype DNA vaccines with human immunodeficiency virus (HIV) Tat-derived transduction sequences for efficacy against 38C13 challenge. The rate of tumor onset was similar for the idiotype and transduction domain-conjugated idiotype vaccine groups. At days 22-23 postchallenge, the number of surviving mice was significantly higher in the group that had received a DNA vaccine consisting of the 38C13 idiotype sequence plus modified Tat transduction sequence, in comparison with the group that received idiotype-only vaccines. Although the overall survival difference was not statistically significant following day 24, a trend toward an increased survival rate for mice receiving idiotype plus Tat-derived transduction domains was maintained through day 106 postchallenge. Thus, the addition to idiotype vaccines of specific sequences that facilitate intracellular transport may have potential to improve the effectiveness of such vaccines.

Original languageEnglish (US)
Pages (from-to)306-308
Number of pages3
JournalHybridoma
Volume25
Issue number5
DOIs
StatePublished - Jan 1 2006

Fingerprint

DNA Vaccines
Lymphoma
Vaccines
B-Cell Lymphoma
Non-Hodgkin's Lymphoma
Amino Acid Sequence
Survival Rate
Clinical Trials
HIV
Membranes
Survival

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Effect of linkage of transduction domain sequences to a lymphoma idiotype DNA vaccine on vaccine effectiveness. / Ashour, Abdel Kader; Petersen, Jason L.; McIlhaney, Mary M.; Vose, Julie Marie; Solheim, Joyce C.

In: Hybridoma, Vol. 25, No. 5, 01.01.2006, p. 306-308.

Research output: Contribution to journalArticle

Ashour, Abdel Kader ; Petersen, Jason L. ; McIlhaney, Mary M. ; Vose, Julie Marie ; Solheim, Joyce C. / Effect of linkage of transduction domain sequences to a lymphoma idiotype DNA vaccine on vaccine effectiveness. In: Hybridoma. 2006 ; Vol. 25, No. 5. pp. 306-308.
@article{58082ec99e554053a53a4d24693b0c97,
title = "Effect of linkage of transduction domain sequences to a lymphoma idiotype DNA vaccine on vaccine effectiveness",
abstract = "Patient idiotype-specific vaccines for treatment of non-Hodgkin's lymphoma have shown promise in clinical trials, encouraging efforts to enhance the effectiveness of idiotype vaccines further. It has previously been found that for some other types of experimental vaccines, the addition of transduction domains has improved vaccine immunogenicity. Transduction domains are short amino acid sequences that are capable of increasing transport through cellular membranes. In this study, we tested murine B cell 38C13 lymphoma idiotype DNA vaccines with human immunodeficiency virus (HIV) Tat-derived transduction sequences for efficacy against 38C13 challenge. The rate of tumor onset was similar for the idiotype and transduction domain-conjugated idiotype vaccine groups. At days 22-23 postchallenge, the number of surviving mice was significantly higher in the group that had received a DNA vaccine consisting of the 38C13 idiotype sequence plus modified Tat transduction sequence, in comparison with the group that received idiotype-only vaccines. Although the overall survival difference was not statistically significant following day 24, a trend toward an increased survival rate for mice receiving idiotype plus Tat-derived transduction domains was maintained through day 106 postchallenge. Thus, the addition to idiotype vaccines of specific sequences that facilitate intracellular transport may have potential to improve the effectiveness of such vaccines.",
author = "Ashour, {Abdel Kader} and Petersen, {Jason L.} and McIlhaney, {Mary M.} and Vose, {Julie Marie} and Solheim, {Joyce C}",
year = "2006",
month = "1",
day = "1",
doi = "10.1089/hyb.2006.25.306",
language = "English (US)",
volume = "25",
pages = "306--308",
journal = "Monoclonal Antibodies in Immunodiagnosis and Immunotherapy",
issn = "2167-9436",
publisher = "Mary Ann Liebert Inc.",
number = "5",

}

TY - JOUR

T1 - Effect of linkage of transduction domain sequences to a lymphoma idiotype DNA vaccine on vaccine effectiveness

AU - Ashour, Abdel Kader

AU - Petersen, Jason L.

AU - McIlhaney, Mary M.

AU - Vose, Julie Marie

AU - Solheim, Joyce C

PY - 2006/1/1

Y1 - 2006/1/1

N2 - Patient idiotype-specific vaccines for treatment of non-Hodgkin's lymphoma have shown promise in clinical trials, encouraging efforts to enhance the effectiveness of idiotype vaccines further. It has previously been found that for some other types of experimental vaccines, the addition of transduction domains has improved vaccine immunogenicity. Transduction domains are short amino acid sequences that are capable of increasing transport through cellular membranes. In this study, we tested murine B cell 38C13 lymphoma idiotype DNA vaccines with human immunodeficiency virus (HIV) Tat-derived transduction sequences for efficacy against 38C13 challenge. The rate of tumor onset was similar for the idiotype and transduction domain-conjugated idiotype vaccine groups. At days 22-23 postchallenge, the number of surviving mice was significantly higher in the group that had received a DNA vaccine consisting of the 38C13 idiotype sequence plus modified Tat transduction sequence, in comparison with the group that received idiotype-only vaccines. Although the overall survival difference was not statistically significant following day 24, a trend toward an increased survival rate for mice receiving idiotype plus Tat-derived transduction domains was maintained through day 106 postchallenge. Thus, the addition to idiotype vaccines of specific sequences that facilitate intracellular transport may have potential to improve the effectiveness of such vaccines.

AB - Patient idiotype-specific vaccines for treatment of non-Hodgkin's lymphoma have shown promise in clinical trials, encouraging efforts to enhance the effectiveness of idiotype vaccines further. It has previously been found that for some other types of experimental vaccines, the addition of transduction domains has improved vaccine immunogenicity. Transduction domains are short amino acid sequences that are capable of increasing transport through cellular membranes. In this study, we tested murine B cell 38C13 lymphoma idiotype DNA vaccines with human immunodeficiency virus (HIV) Tat-derived transduction sequences for efficacy against 38C13 challenge. The rate of tumor onset was similar for the idiotype and transduction domain-conjugated idiotype vaccine groups. At days 22-23 postchallenge, the number of surviving mice was significantly higher in the group that had received a DNA vaccine consisting of the 38C13 idiotype sequence plus modified Tat transduction sequence, in comparison with the group that received idiotype-only vaccines. Although the overall survival difference was not statistically significant following day 24, a trend toward an increased survival rate for mice receiving idiotype plus Tat-derived transduction domains was maintained through day 106 postchallenge. Thus, the addition to idiotype vaccines of specific sequences that facilitate intracellular transport may have potential to improve the effectiveness of such vaccines.

UR - http://www.scopus.com/inward/record.url?scp=33947222070&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33947222070&partnerID=8YFLogxK

U2 - 10.1089/hyb.2006.25.306

DO - 10.1089/hyb.2006.25.306

M3 - Article

VL - 25

SP - 306

EP - 308

JO - Monoclonal Antibodies in Immunodiagnosis and Immunotherapy

JF - Monoclonal Antibodies in Immunodiagnosis and Immunotherapy

SN - 2167-9436

IS - 5

ER -